Oncoleader

Articles

Orca Bio’s Precision Cell Therapy “Orca-T” Proves Successful In Pivotal Phase 3 Trial

ruliff andrean l76z1uH8k24 unsplash e1739491761896
red and blue emblem oncoleader transparent

Subscribe to the newsletter

Get emailed whenever a new video, article, or course is released. This gives you instant access to all of our fresh content.

Orca Bio is a late-stage biotechnology company developing “precision” cell therapies that are completely redefining stem cell transplants. Get ready to hear more about them in the very near future because the company just announced that they will be presenting positive phase 3 data on their Orca-T program at the 51st Annual Meeting of the European Society for Blood and Marrow Transplantation from March 30th – April 2nd.

Here’s what you need to know.

Log in or sign up to access this article.

Already a member? Login

Articles Only

Get access to
written articles
$ 15 / month
  • Written Articles
Get Access

Articles Only

Get access to
written articles
$ 150 / year
  • Written Articles
Get Access
ANNUAL

Full Access

Full access to articles, videos, and courses
$ 200 / year
  • Full Access to Articles, Videos & Courses
  • BEST VALUE
Get Full Access
ANNUAL
Become a Leader in Oncology 2

Recent Videos

All Videos
All Articles

LATEST IN ONCOLOGY BIOTECH

Recent Videos

Tumor-Activated Therapeutics
Autolus’ CAR-T Cells Receive FDA Approval
Oncoleader MCT11 screenshot cancer oncology immunotherapy
MCT11: Combatting T Cell Exhaustion to Enhance ICIs and CAR-Ts
Gene Delivery as Cancer Immunotherapy
Review Your Cart
0
Add Coupon Code
Subtotal
Checkout